Bhat Laxminarayan - 25 Apr 2023 Form 4 Insider Report for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Role: President and CEO, Director, 10%+ Owner
Signature: /s/ Narayan Prabhu, Attorney-in-Fact
Issuer symbol: RVPH
Transactions as of: 25 Apr 2023
Net transactions value: $0
Form type: 4
Filing time: 27 Apr 2023, 16:31:00 UTC
Next filing: 17 Sep 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVPH	Stock Option (right to buy)	Award	$0	+443,000		$0.000000	443,000	25 Apr 2023	Common Stock, par value $0.0001 per share	443,000	$6.74	Direct	F1
transaction	RVPH	Stock Option (right to buy)	Award	$0	+150,000		$0.000000	150,000	25 Apr 2023	Common Stock, par value $0.0001 per share	150,000	$6.74	By Spouse	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the "Reporting Person"), by the Issuer's compensation committee on April 25, 2023 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan.
F2	Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Issuer's compensation committee on April 25, 2023 (the "Grant Date") in accordance with the terms of the 2020 Plan. The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan.

Content

Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the "Reporting Person"), by the Issuer's compensation committee on April 25, 2023 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan.

Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Issuer's compensation committee on April 25, 2023 (the "Grant Date") in accordance with the terms of the 2020 Plan. The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan.